This company has been marked as potentially delisted and may not be actively trading. Provention Bio (PRVB) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PRVB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Macrogenics Inc MGNXDecember 29, 2023 | morningstar.comMCambridge Investment Research Advisors Inc. Increases Stock Holdings in Provention Bio, Inc. (NASDAQ:PRVB)May 29, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Stock Holdings Increased by Swiss National BankMay 26, 2023 | marketbeat.comArizona State Retirement System Purchases 7,068 Shares of Provention Bio, Inc. (NASDAQ:PRVB)May 25, 2023 | marketbeat.comSG Americas Securities LLC Purchases New Position in Provention Bio, Inc. (NASDAQ:PRVB)May 17, 2023 | marketbeat.comZurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Provention Bio, Inc. (NASDAQ:PRVB)May 8, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Given Consensus Rating of "Hold" by BrokeragesMay 7, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Shares Purchased by New York State Common Retirement FundMay 3, 2023 | marketbeat.comSanofi/Provention: innovative diabetes drug is a good fitMay 1, 2023 | finance.yahoo.comThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 29, 2023 | finance.yahoo.comSanofi completes Provention Bio acquisitionApril 28, 2023 | seekingalpha.comEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finance.yahoo.comProvention Bio (Nasdaq:PRVB) HeadlineTrading was temporarily halted for "PRVB" at 07:04 PM with a stated reason of "News pending."...April 27, 2023 | marketbeat.comSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 27, 2023 | finanznachrichten.deProvention Bio gains after HSR waiting period for Sanofi deal expiredApril 26, 2023 | seekingalpha.comPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 26, 2023 | benzinga.comPRVB Apr 2023 23.000 putApril 22, 2023 | finance.yahoo.comProvention Bio, Inc. (NASDAQ:PRVB) Receives Average Recommendation of "Hold" from AnalystsApril 12, 2023 | marketbeat.comSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationApril 11, 2023 | msn.comRice Hall James & Associates LLC Has $1.92 Million Holdings in Provention Bio, Inc. (NASDAQ:PRVB)April 9, 2023 | marketbeat.comOppenheimer Equities Analysts Cut Earnings Estimates for Provention Bio, Inc. (NASDAQ:PRVB)April 3, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their EstimatesApril 2, 2023 | finance.yahoo.comGaithersburg’s Novavax locks in consulting deal with outgoing R&D headMarch 27, 2023 | bizjournals.comProvention Bio, Inc. (NASDAQ:PRVB) Given Average Recommendation of "Hold" by AnalystsMarch 18, 2023 | marketbeat.com(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?March 17, 2023 | benzinga.comQ4 2022 MacroGenics Inc Earnings CallMarch 16, 2023 | finance.yahoo.comProvention Bio's Earnings OutlookMarch 15, 2023 | benzinga.comProvention Bio (NASDAQ:PRVB) Earns "Neutral" Rating from Sumitomo Mitsui Financial GroupMarch 15, 2023 | marketbeat.comSMBC Nikko Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comJefferies Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comProvention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealMarch 14, 2023 | proactiveinvestors.comShort Volatility Alert: Provention Bio IncMarch 14, 2023 | benzinga.com4 Analysts Have This to Say About Provention BioMarch 14, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with SanofiMarch 13, 2023 | benzinga.comProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallMarch 13, 2023 | finance.yahoo.comSanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drugMarch 13, 2023 | msn.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. BuyoutMarch 13, 2023 | benzinga.comPRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to ShareholdersMarch 13, 2023 | businesswire.comWhy Is Provention Bio (PRVB) Stock Up 263% Today?March 13, 2023 | investorplace.comProvention Bio Stock Soars on $2.9 Billion Acquisition by SanofiMarch 13, 2023 | barrons.comSanofi to Acquire Provention Bio for Around $2.9 BlnMarch 13, 2023 | wsj.comFrance's Sanofi to acquire US-based Provention Bio for $2.9 blnMarch 13, 2023 | reuters.comSanofi To Buy Provention Bio For Around $2.9 Bln In CashMarch 13, 2023 | markets.businessinsider.comUPDATE 1-France's Sanofi to acquire US-based Provention Bio for $2.9 blnMarch 13, 2023 | finance.yahoo.comSanofi to buy Provention Bio in deal worth $2.9 billionMarch 13, 2023 | finance.yahoo.comWill Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should KnowMarch 9, 2023 | finance.yahoo.comProvention Bio (PRVB) Scheduled to Post Quarterly Earnings on ThursdayMarch 9, 2023 | marketbeat.com390,800 Shares in Provention Bio, Inc. (NASDAQ:PRVB) Purchased by Palo Alto Investors LPMarch 6, 2023 | marketbeat.comProvention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A WorryFebruary 24, 2023 | seekingalpha.comProvention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023February 23, 2023 | finance.yahoo.com Get Provention Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRVB Media Mentions By Week PRVB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRVB News Sentiment▼1.560.92▲Average Medical News Sentiment PRVB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRVB Articles This Week▼00▲PRVB Articles Average Week Get the Latest News and Ratings for PRVB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Provention Bio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Jyong Biotech News Today MorphoSys News Today Zymeworks News Today MBX Biosciences News Today Aerovate Therapeutics News Today BioAge Labs News Today Eliem Therapeutics News Today Cybin News Today Virios Therapeutics News Today OS Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRVB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provention Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRVB Stock Alerts